6996 Panoramica delle azioni Antengene Corporation Limited, società biofarmaceutica, è impegnata nello sviluppo di nuove terapie oncologiche nella Grande Cina e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Antengene Corporation Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Antengene Prezzi storici delle azioni Prezzo attuale dell'azione HK$0.83 Massimo di 52 settimane HK$1.55 Minimo di 52 settimane HK$0.50 Beta 0.72 Variazione di 1 mese 27.69% Variazione a 3 mesi -2.35% Variazione di 1 anno -43.92% Variazione a 3 anni -85.49% Variazione a 5 anni n/a Variazione dall'IPO -95.46%
Notizie e aggiornamenti recenti
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025 Jan 22
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
New minor risk - Share price stability Sep 17 Vedi altri aggiornamenti
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025 Jan 22
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
New minor risk - Share price stability Sep 17
Consensus revenue estimates decrease by 32%, EPS upgraded Aug 30
First half 2024 earnings: EPS and revenues exceed analyst expectations Aug 27
Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024 Aug 01
Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024 Jul 31
Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country Jul 06
Consensus revenue estimates decrease by 63%, EPS upgraded Mar 29
Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024 Mar 23
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 23
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study Mar 20
Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024 Mar 12
Consensus revenue estimates decrease by 24%, EPS upgraded Jan 11
Revenues Tell The Story For Antengene Corporation Limited (HKG:6996) Jan 09
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Dec 14
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States Dec 11
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Dec 06
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day Nov 17
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 Sep 22
The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26% Sep 20
New minor risk - Shareholder dilution Sep 20
Consensus revenue estimates decrease by 16%, EPS upgraded Sep 06
First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022) Aug 26
Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 16
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jul 17
New minor risk - Share price stability Jul 07
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jun 03
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers May 24
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 May 18
Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates Apr 03
We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate Feb 19
Antengene Corporation Limited Announces Executive Changes Dec 07
Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer Nov 16
Less than half of directors are independent Nov 16
Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting Nov 08
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth Nov 05
Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037 Nov 03
Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors Nov 01
Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma Oct 22
First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021) Sep 02
Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma Aug 03 Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022
We Think Antengene (HKG:6996) Can Afford To Drive Business Growth Jun 28
Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors Jun 08
Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 Jun 07
Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors May 31
Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas May 23
Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China May 19
Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 18
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 16
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress May 14
Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018 Apr 27
Less than half of directors are independent Apr 27
Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine Apr 07
Antengene Corporation Limited Announces Management Changes Mar 31
Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes Mar 30
We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely Mar 08 Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 Feb 07
Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors Dec 30
Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial Dec 20
National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China Dec 18
Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting Dec 15
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors Dec 13
We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely Nov 18
Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China Aug 24
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth Aug 17
Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma Jul 23
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) Jul 07
Non-Executive Director Zhen Li has left the company Jun 24
Non-Executive Director Zhen Li has left the company Jun 23
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 Jun 04
Antengene Corporation Limited Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome May 28
Antengene Corporation Limited Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial May 17
Antengene Corporation Limited Receives the Approval of the Investigational New Drug Application by the National Medical Products Administration May 15
Antengene Corporation Limited Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies May 14
Antengene Corporation Limited Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer May 13
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines May 07
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth Apr 29
Non-Executive Director has left the company Mar 27
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea Mar 15
New 90-day low: HK$15.24 Mar 08
Antengene Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021 Mar 06
Antengene Corporation Limited Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA Feb 25
What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares? Feb 22
Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage Feb 01
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM Jan 29
Antengene Corporation Limited Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study Jan 26
Antengene Corporation Limited Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer Jan 05
Antengene Corporation Limited Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL Jan 04
National Medical Products Administration Approves the Investigational New Drug Application for Antengene Corporation Limited's ATG-010 Dec 20
Antengene Corporation Limited Announces Acceptance of IND Application in China for A Phase 3 Clinical Trial of Atg-010 (Selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of rrMM Dec 12
Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology Dec 10 Rendimenti per gli azionisti 6996 HK Pharmaceuticals HK Mercato 7D 20.3% 1.6% 1.2% 1Y -43.9% 0.3% 20.6%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 6996 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento 0.3 % nell'ultimo anno.
Rendimento vs Mercato: 6996 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 20.6 % nell'ultimo anno.
Volatilità dei prezzi Is 6996's price volatile compared to industry and market? 6996 volatility 6996 Average Weekly Movement 9.2% Pharmaceuticals Industry Average Movement 4.9% Market Average Movement 6.5% 10% most volatile stocks in HK Market 13.9% 10% least volatile stocks in HK Market 3.0%
Prezzo delle azioni stabile: 6996 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Hong Kong.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di 6996 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Antengene Corporation Limited, società biofarmaceutica, è impegnata nello sviluppo di nuove terapie oncologiche nella Grande Cina e a livello internazionale. Le attività commercializzate dell'azienda comprendono ATG-010 (selinexor), un composto SINE orale per il trattamento di varie neoplasie ematologiche e tumori solidi, tra cui il mieloma multiplo recidivato/refrattario (rrMM), il linfoma diffuso a grandi cellule B recidivato/refrattario e il mieloma multiplo (MM) in pazienti adulti in Cina continentale, Singapore, Australia, Hong Kong, Macao e Taiwan. I suoi prodotti candidati in fase avanzata comprendono ATG-008 (onatasertib), un inibitore della chinasi mTOR per il trattamento del cancro alla cervice e di altri tumori solidi avanzati.
Mostra di più Antengene Corporation Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Antengene con la sua capitalizzazione di mercato? 6996 statistiche fondamentali Capitalizzazione di mercato HK$563.94m Guadagni(TTM ) -HK$566.03m Ricavi(TTM ) HK$59.93m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 6996 Conto economico (TTM ) Ricavi CN¥56.07m Costo del fatturato CN¥8.50m Profitto lordo CN¥47.57m Altre spese CN¥577.09m Guadagni -CN¥529.52m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.78 Margine lordo 84.84% Margine di profitto netto -944.43% Rapporto debito/patrimonio netto 18.1%
Come si è comportato 6996 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/23 19:57 Prezzo dell'azione a fine giornata 2025/01/23 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Antengene Corporation Limited è coperta da 7 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Ziyu He China International Capital Corporation Limited Wangbin Zhou Citigroup Inc Ruili Bian Citigroup Inc
Mostra 4 altri analisti 
